Search clinical trials for: AG-120 (Ivosidenib)

Total 5841 results

Agios Pharmaceuticals, Inc.

Completed

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

Healthy

United States
Agios Pharmaceuticals, Inc.

Approved for marketing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Acute Myeloid Leukemia | Relapsed Pediatric AML | Relapsed Adult AML
Agios Pharmaceuticals, Inc.

Completed

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Hepatic Impairment

United States
Institut de Recherches Internationales Servier

Completed

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

Metastatic Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States, Spain, Korea, Republic of, Italy, France, United Kingdom
Memorial Sloan Kettering Cancer Center
Agios Pharmaceuticals, Inc.

Recruiting

AG-120 in People With IDH1 Mutant Chondrosarcoma

Chondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3

United States
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France, Italy
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Glioma

United States
Institut de Recherches Internationales Servier

Completed

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Glioma | Cholangiocarcinoma | Chondrosarcoma | Other Advanced Solid Tumors

United States, France
Agios Pharmaceuticals, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

Healthy Volunteers

United States
Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Cerecin

Withdrawn

Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

Alzheimer Disease
Celgene

Active, not recruiting

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, France, Italy, Korea, Republic of, Spain, United Kingdom, Australia, Canada, Germany, Netherlands, Portugal, Switzerland, Belgium, Sweden
Alice Mims
National Cancer Institute (NCI)

Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Acute Myeloid Leukemia

United States
Servier Affaires Médicales

Recruiting

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe)

Cholangiocarcinoma

France, Netherlands, Spain, Belgium, Sweden, Italy, Australia, Austria, Germany, United Kingdom
M.D. Anderson Cancer Center

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Penn State University
Jenny Craig, Inc.

Completed

The Influence of Satiation Measures on the Portion Size Effect

Feeding Behavior

United States
Penn State University

Terminated

The Role of Satiety in the Effect of Portion Size on Intake

Feeding Behavior

United States
Vedic Lifesciences Pvt. Ltd.
Enovate Biolife Pvt Ltd

Completed

A Study to Evaluate Efficacy of IP on Alertness and Mental Fatigue (ALERMEN)

Mental Fatigue

India
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Yale University

Withdrawn

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Healthy Volunteers

United States
Molnlycke Health Care AB

Completed

Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers

Venous Leg Ulcers | Mixed Leg Ulcers

France, Germany, Netherlands, Czech Republic
Agios Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Healthy Male Participants

United States
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Not yet recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
CStone Pharmaceuticals

Completed

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Relapsed or Refractory Acute Myeloid Leukemia

China
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Healthy Volunteers

United States
Clinical Nutrition Research Centre, Singapore

Completed

The Lunch Study: the Combined Effects of Food Texture and Portion Size on Intake

Satiation

Singapore
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Hospital General Universitario Elche

Unknown

RYGB AL 150cm BPL 100cm vs RYGB AL 100cc BPL 150cm

Weight Loss
Joint Authority for Päijät-Häme Social and Health...

Recruiting

Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service (AGS)

Arthroplasty Complications | Dysglycemia

Finland
Agios Pharmaceuticals, Inc.

Terminated

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Lymphoma

United States
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Agios Pharmaceuticals, Inc.

Completed

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy | Japanese | Non-Asian

United States
Ahn-Gook Pharmaceuticals Co.,Ltd
Hanyang University; Ewha Womans University; Konkuk University Medical Center; Kyunghee... and other collaborators

Completed

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup"

Bronchitis | Acute Upper Respiratory Tract Infections

Korea, Republic of
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
DermBiont, Inc.

Active, not recruiting

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Dermatosis Papulosa Nigra

United States
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
Molnlycke Health Care AB

Recruiting

Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

Partial-thickness Burn

United States

Search clinical trials for: AG-120 (Ivosidenib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations